A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 790
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : RTX
Long Form : rituximab
No. Year Title Co-occurring Abbreviation
2020 A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. BLM, BTZ
2020 Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. ANCA, EGPA, GC
2020 Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. RA-BR, TNFi
2020 Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: A network meta-analysis. GC, LEF, MMF, NMA, OR, RLN, TAC
2020 Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. FI, HR, IR, RA-ILD
2020 Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score. ABA, DMARDs, RA, TCZ, TNFi
2020 Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. SDNS
2020 Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. HBcAb, HBsAb, HBsAg, HBV, RA
2020 Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma. NHL, PEG
10  2020 Rituximab in AChR subtype of myasthenia gravis: systematic review. MG
11  2020 Rituximab in multiple sclerosis at general hospital level. MS, RRMS
12  2020 Rituximab treatment for IgA vasculitis: A systematic review. IgAV
13  2020 Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia. AHA, ES, PH, PID
14  2020 Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E. HEV, RBV
15  2020 Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome. HACA, NS, RISS
16  2020 Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune diseases receiving rituximab: a retrospective cohort study. AID, IgRT, SIE
17  2020 Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. CD20
18  2020 Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review. CTD, IIMs, ILD, SSc
19  2020 The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation. PV
20  2020 [Use of rituximab in maintenance treatment of pemphigus: A retrospective series]. CCR, PS, PV
21  2019 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. GC, SLE
22  2019 A comprehensive review of rituximab therapy in rheumatoid arthritis patients. RA
23  2019 A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus. MS, PPMS, RRMS, SPMS
24  2019 An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. ADCC, ATZ, B-NHL, biAb, CDC, CLL, mAb
25  2019 Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study. LN
26  2019 Arthritis in primary Sjogren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. CCP, CRI, HCQ, MTX, pSS
27  2019 B cells in Graves' Orbitopathy: more than just a source of antibodies? ---
28  2019 Biologics for childhood systemic vasculitis. AAV, CYC, IVIG, KD, RAVE
29  2019 Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis. AEs, RA
30  2019 Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. ABA, bDMARD, CHF, MI, NMA, PAD, RCT, TCZ, TNFi
31  2019 Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study. AS, BALF, HRCT, ILD
32  2019 Clinical efficacy and safety of rituximab in lupus nephritis. CR, LN, TR
33  2019 Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series. IVIG, PTM
34  2019 Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. CYC, DM, MDA5, RP
35  2019 Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? PV
36  2019 Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis. ITP, RCTs, TPO-RAs
37  2019 Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome. ---
38  2019 Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. AAV, CIs
39  2019 Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for Targeting of B-cell Lymphoma. PEO-PBCL, PEO-PCL, RTX-PEG-DSPE
40  2019 Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran. AZA, NMOSD
41  2019 Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia. AE, CLL, HDMP, PFS
42  2019 Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. HUVECs, RA, SLE
43  2019 Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. SDNS
44  2019 Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. MG, MG-ADL, MMT, QMGS, QOL
45  2019 Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. CYC, GPA, MPA, VDI
46  2019 Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. IQR, SSc
47  2019 Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. DDCNS
48  2019 Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. AEs, ARR, CENTRAL, EDSS, HR, MMF, NMOSD, RCT
49  2019 Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. ARR, EDSS, MD, NMO
50  2019 Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. AEs, CR, Dsg, NDPs, PDAI, PTPs, PV
51  2019 Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. ARR, IND-A, TTFR
52  2019 Efficacy of rituximab in resistant palindromic rheumatism: first report in literature. csDMARDs, PR, RA
53  2019 Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates. CNS, LNs, mAb, NHPs
54  2019 Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study. ---
55  2019 Fatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition? BLM, FASL, ITP, MSN
56  2019 Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. GCs, IM, ORs
57  2019 Granulomatosis with polyangiitis with isolated orbital involvement in children: a case report successfully treated with Rituximab and review of literature. GPA
58  2019 HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? HBV
59  2019 High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. Ab, AChR, MG, MuSK
60  2019 Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery? SDNS, SRNS
61  2019 Immunosuppressive treatment for peripheral neuropathies in Sjogren's syndrome - a systematic review. AZA, CP, GC, IV IG, MTX, SS
62  2019 Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis. MTX, OR, RA, TNFi
63  2019 Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. DMTs, MRI, RRMS
64  2019 Iranian guideline for rituximab therapy in pemphigus patients. PV
65  2019 Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome. PSL
66  2019 Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. PAPS
67  2019 Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. IgG4-RD
68  2019 Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. ---
69  2019 Low-dose rituximab as induction therapy for ANCA-associated vasculitis. AAV, BVAS, CR, LD, VDI
70  2019 Lower cranial nerve palsy during radiotherapy for glottic cancer in a patient with Wegener's granulomatosis: An interesting case report. CYC, WG
71  2019 Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes. ARRs, AZP, DMDs, MMF, MOG, MOG-Ab, ON
72  2019 Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. CI, FGL, HRs, MS, NTZ, RRMS
73  2019 Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. ---
74  2019 Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort. CYC
75  2019 Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. CNI, NS
76  2019 Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. ARR, MS, NMO, NMOSD
77  2019 Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism. ADA, bDMARDs, ETA, RA, TCZ
78  2019 Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia. EBV, KT, PTLD
79  2019 Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. allo-SCT, EBV
80  2019 Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. RMDs, SIEs
81  2019 Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. CI, HR, iTTP
82  2019 Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan. DAS28-ESR, EULAR, OR, RA
83  2019 Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. GISC, LT-MCS, MCS, S-MCS, TPE
84  2019 Refractory Takayasu arteritis successfully treated with rituximab: case-based review. TAK
85  2019 Remission maintenance in ANCA-associated vasculitis: does one size fit all? AAV, ANCA, GPA, MPA
86  2019 Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. ICD, IVIG, PF, PV
87  2019 Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. CR, IMT, LRMD, PF, PV
88  2019 Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. RMT, SLE
89  2019 Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. MN
90  2019 Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth. SRNS, SSNS
91  2019 Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. GPA
92  2019 Rituximab in connective tissue disease-associated interstitial lung disease. CTD, FVC, HRCT, ILD, NSIP, UIP
93  2019 Rituximab in routine care ofsevere active rheumatoid arthritis : Aprospective, non-interventional study inGermany. DMARD, HAQ, RA, TNF
94  2019 Rituximab in systemic sclerosis: A protocol for systematic review. SR, SSc
95  2019 Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. anti-HMGCR
96  2019 Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis. ARAs, RA
97  2019 Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort. ANCA
98  2019 Rituximab prevents and reverses cardiac remodeling by depressing B cell function in mice. HF, TAC, WT
99  2019 Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. GCs, IS, mRS, PCNSV
100  2019 Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events. CR, PR, RV